Printer Friendly

U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST

      U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS
             TO PRODUCTS IN LATIN AMERICA AND FAR EAST
    WEST CONSHOHOCKEN, Pa., Nov. 19 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS), a pharmaceutical company specializing in the development and commercialization of anti-cancer compounds, today announced that it has signed an agreement in principle with Schering- Plough Corp. directed toward granting it marketing rights to Hexalen(R), Ethyol(R), WR-151327, PALA and Rogletimide for a number of countries in Latin America and the Far East.
    Hexalen has been approved by the U.S. Food and Drug Administration and is used in the treatment of ovarian cancer.  Ethyol, for which a New Drug Application has been filed with the FDA, is a radiation- and chemotherapy-protective agent.  PALA, a drug in the final stages of development, is aimed at enhancing the activity of certain chemotherapeutic agents.  Rogletimide is a drug for the treatment of breast cancer.
    "In Schering-Plough, we have chosen a company that historically has had strong marketing, sales and product registration capabilities in the oncology market, which will help to optimize the potential of these products in these regions," said Philip S. Schein, M.D., chairman and chief executive officer.  "We are pleased to be affiliated with this type of organization.  The completion of this agreement will represent an important step to the company as we attempt to expand our efforts internationally in markets where U.S. Bioscience may have a limited chance of succeeding on its own."
    Known for the quality of its products and the integrity of its people, Schering-Plough, based in Madison, N.J., is a research-based company involved in the research, development, manufacturing and marketing of pharmaceutical and healthcare products worldwide.
    Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases.
    -0-                 11/19/91
    /CONTACT:  Robert I. Kriebel of U.S. Bioscience, 215-832-4503; or Charles Versaggi of Versaggi & Associates for U.S. Bioscience, 408-358-4162 or 408-395-1877/
    (UBS) CO:  U.S. Bioscience ST:  Pennsylvania IN:  MTC SU: JL -- SJ003 -- 4772 11/19/91 08:03 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1991
Words:359
Previous Article:U.S. BIOSCIENCE GAINS EUROPEAN MARKETING RIGHTS TO OVARIAN CANCER DRUG
Next Article:SECURITY ENVIRONMENTAL SYSTEMS ANNOUNCES INCREASE IN OPERATING REVENUES
Topics:


Related Articles
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
SCHERING-PLOUGH AND U.S. BIOSCIENCE
SCHERING-PLOUGH LICENSES ORAL ANDROGEN TO SPI PHARMACEUTICALS
SCHERING-PLOUGH AND ORION SIGN AGREEMENT ON U.S. MARKETING RIGHTS FOR BREAST CANCER TREATMENT
ALZA AND U.S. BIOSCIENCE ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT FOR ETHYOL(R) IN THE UNITED STATES
Schering-Plough Sells Rights to Interleukin-11 to American Home Products Corporation
Schering-Plough and Reckitt & Colman in Agreement on Worldwide Marketing Rights for Buprenorphine Products
Schering-Plough and Chugai Pharmaceutical In Agreement on Marketing Rights For New Treatment of Psoriasis
Helsinn Healthcare SA and Schering-Plough announce licensing agreement for palonosetron in select global markets.
Schering-Plough and Helsinn Healthcare SA Announce Licensing Agreement For Palonosetron in Select Global Markets.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters